Different neuroendocrine profiles of remitted and nonremitted schizophrenic patients

Yazici K., Yazici A., Taneli B.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, vol.26, no.3, pp.579-584, 2002 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 26 Issue: 3
  • Publication Date: 2002
  • Doi Number: 10.1016/s0278-5846(01)00311-6
  • Page Numbers: pp.579-584


Background: Thyrotropin-releasing hormone (TRH) test and Dexamethasone Suppression Test (DST) are two neuroendocrine tests that have been extensively used in an attempt to predict treatment response and outcome in schizophrenia. The objectives of this study were to investigate (1) the relationship between TRH test and DST and various psychiatric symptoms and (2) the potential value of these tests in prediction of short-term outcome in schizophrenic patients. Methods: TRH test and DST were administered to 58 patients with schizophrenia. All patients were evaluated with a battery of rating scales before neuroendocrine test procedures and at regular intervals for I year. Patients were divided into two groups as remitted (RP; n = 30) and nonremitted patients (NRP; n = 28). Baseline results of these two groups were compared with each other and 30 healthy controls. Results: Basal levels of total T-3 (T-3T) and free T-3 (T-3F) were higher in RP group than controls. Basal prolactin (PRL) level was higher in R-P group, but not in NRP, compared to controls. Basal growth hormone (GH) and thyroidstimulating hormone (TSH) levels of NRP were significantly higher than those of RP. DST nonsuppression was observed at a significantly higher rate in RP than NRP and control group. Blunted TSH response rate in RP group was higher significantly compared to other two groups. Conclusions: The data implicate that higher basal TSH and GH levels may be associated with a poorer treatment response, whereas higher total and free T3 levels, a blunted TSH response to TRH and nonsuppression on the DST may indicate a better response in schizophrenics. (C) 2001 Elsevier Science Inc. All rights reserved.